ArticleFrontiers in microbiology2024
Prophylactic phage administration provides a time window for delayed treatment of vancomycin-resistant
Article in Frontiers in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Microbial architects of cigar fermentation: a critical review of beneficial roles in quality enhancement and detrimental potential for mould spoilage.Archives of microbiology · 2026Review
- Phage-Microbiota Interactions in the Gut: Implications for Health and Therapeutic Strategies.Probiotics and antimicrobial proteins · 2026Review
- Quorum sensing disruption in Enterobacter spp.: unlocking new therapeutic pathways against multidrug-resistant infections.Antonie van Leeuwenhoek · 2026Review
- Alginate encapsulation enhanced the gastrointestinal stability and bactericidal efficacy of an optimized Salmonella phage cocktail for oral delivery in poultry feed.Poultry science · 2026Article
- Newly isolatedFrontiers in microbiology · 2026Article
- Phage therapy and the microbiome in hematologic malignancies: opportunities, mechanisms, and early evidence.Journal of cancer research and clinical oncology · 2025Review
- Exploring the potential of bacterial-derived EVs for targeted enzyme replacement therapy: mechanisms, applications, and future directions.Archives of microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Vancomycin-resistant Methods: The biological and genomic characteristics of a novel lytic phage specific to VRE were investigated. Its Results: We isolated and characterized a novel lytic phage, vB_EfaS-1017, specific to vancomycin-resistant Discussion: These findings underscore the potential of phage-antibiotic combinations as a superior therapeutic strategy against VRE infections. The observed synergy between phages and antibiotics highlights a promising approach to overcoming bacterial resistance and improving clinical outcomes. Furthermore, prophylactic phage administration may provide a critical time window for effective delayed treatment. Further preclinical research is essential to refine phage therapy protocols for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.